Identification of Common Data Elements from Pivotal FDA Trials

Area of Science:

• Clinical data management
• Drug development research
• Regulatory science

Background:

• Establishing a universally accepted set of common data elements (CDEs) for clinical research is complex.
• Clinical trial registries contain extensive outcome data, posing challenges for efficient analysis.
• A focused approach is needed to distill this information into a manageable and meaningful dataset.

Purpose of the Study:

• To identify a core set of significant common data elements (CDEs) from pivotal clinical trials.
• To streamline data analysis by focusing on trials critical for regulatory drug approval.
• To group identified CDEs by medical condition for practical application.

Main Methods:

• Selected pivotal trials submitted to the Food and Drug Administration (FDA) for drug approval.
• Extracted primary outcome data from these pivotal trials.
• Analyzed 172 data elements across 192 pivotal trials for 100 drugs.

Main Results:

• Identified a refined set of 76 common data elements (CDEs).
• These CDEs were derived from a comprehensive analysis of pivotal trial data.
• The identified CDEs are organized by medical condition.

Conclusions:

• The proposed set of 76 CDEs represents a significant and usable subset of clinical trial data.
• Focusing on pivotal trials provides a practical method for identifying essential data elements.
• This curated list of CDEs, categorized by medical condition, aids in efficient data analysis and comparison.